异基因造血干细胞移植治疗慢性粒-单核细胞白血病的临床结局  

Clinical outcomes of allogeneic hematopoietic stem cell transplantation for chronic myelomonocytic leukemia

作　　者：张晓辉[1] 周建英 Zhang Xiaohui;Zhou Jianying(Peking University People’s Hospital,Peking University Institute of Hematology,National Clinical Research Center for Hematologic Disease,Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation,Beijing100044,China)

机构地区：[1]北京大学人民医院、北京大学血液病研究所、国家血液系统疾病临床医学研究中心、造血干细胞移植北京市重点实验室,北京100044

出　　处：《中华血液学杂志》2024年第1期18-21,共4页Chinese Journal of Hematology

摘　　要：慢性粒-单核细胞白血病(CMML)是一种来源于骨髓造血干细胞的克隆性疾病,预后较差。异基因造血干细胞移植(allo-HSCT)是可治愈CMML的方法之一。患者移植后结局受疾病特征和患者共病等多种因素影响。根据现有预后分层系统,筛选出适合移植的CMML患者并早期移植,有利于其长期生存。医生可根据新开发的移植预后模型评估移植后CMML患者的生存情况并作出针对性的医疗决策。Chronic myelomonocytic leukemia(CMML)is a clonal disease derived from bone marrow hematopoietic stem cells,with a poor prognosis.Allogeneic hematopoietic stem cell transplantation(allo-HSCT)is one of the curable methods for CMML.The outcome of patient transplantation is influenced by various factors such as disease characteristics and comorbidities.Based on the existing prognostic stratification system,screening suitable CMML patients for transplantation and early transplantation is beneficial for their long-term survival.Doctors can evaluate the survival status of CMML patients after transplantation based on the newly developed transplant prognosis model and make targeted medical decisions.

关 键 词：慢性粒-单核细胞白血病 异基因造血干细胞移植 临床结局 

分 类 号：R457.7[医药卫生—治疗学] R733.72[医药卫生—临床医学]